16 Jun 2025
💊FDA Notice for Oncologic Drugs Advisory Committee Meeting
Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologic License Application (BLA) 761440 for Belantamab Mafodotin
Summary
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The content involves regulatory compliance and public comment opportunities regarding the Biologics License Application for a cancer treatment drug, impacting pharmaceutical companies and stakeholders in drug approval processes.